StockData
Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. (NAUT) stock

NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 6/30
$2.12−0.05 (-2.30%)

Close on Nov 20, 2026Market cap $270.03MP/E –Yield –

Nautilus Biotechnology free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Nautilus Biotechnology's free cash flow for the twelve months ending Sep 30, 2026 was -$55.14M. For fiscal 2025 it was -$51.97M. The highest annual figure on record is -$14.92M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$51.97M–
FY2024Dec 31, 2024-$61.27M–
FY2023Dec 31, 2023-$54.15M–
FY2022Dec 31, 2022-$48.13M–
FY2021Dec 31, 2021-$41.51M–
FY2020Dec 31, 2020-$14.92M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$14.73M–
Q2 FY2026Jun 30, 2026-$14.18M–
Q1 FY2026Mar 31, 2026-$13.61M–
Q4 FY2025Dec 31, 2025-$12.62M–
Q3 FY2025Sep 30, 2025-$11.45M–
Q2 FY2025Jun 30, 2025-$13.75M–
Q1 FY2025Mar 31, 2025-$14.16M–
Q4 FY2024Dec 31, 2024-$14.56M–
Q3 FY2024Sep 30, 2024-$13.82M–
Q2 FY2024Jun 30, 2024-$15.97M–
Q1 FY2024Mar 31, 2024-$16.91M–
Q4 FY2023Dec 31, 2023-$14.31M–
Q3 FY2023Sep 30, 2023-$12.61M–
Q2 FY2023Jun 30, 2023-$14.01M–
Q1 FY2023Mar 31, 2023-$13.22M–
Q4 FY2022Dec 31, 2022-$10.61M–
Q3 FY2022Sep 30, 2022-$10.53M–
Q2 FY2022Jun 30, 2022-$14.18M–
Q1 FY2022Mar 31, 2022-$12.82M–
Q4 FY2021Dec 31, 2021-$11.51M–
Q3 FY2021Sep 30, 2021-$14.45M–
Q2 FY2021Jun 30, 2021-$8.82M–
Q1 FY2021Mar 31, 2021-$6.74M–
Q4 FY2020Dec 31, 2020-$5.03M–
Q3 FY2020Sep 30, 2020-$3.63M–

More Nautilus Biotechnology figures

See a number that looks wrong?